ASH 2024 Summary: Myeloma Highlights and Impact on Practice

2024 ASH Annual Meeting Insights Hub

H. Hashmi

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Result…

2024 ASH Annual Meeting Insights Hub

U. Shah

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Louisville Hematology Highlights

K. Patel, S. Usmani

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

Adeel Khan

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

CAR-T Strategies and Clinical Considerations for R/R MM

Moffitt Cancer Center

K. Patel

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

Making Sense in R/R Myeloma: Guideline-Based Current Approaches

Saurabh Chhabra

ASH 2024 Insights: Efficacy of Anti-BCMA CAR-T in Myeloma Patients P…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt